{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:22:53Z","timestamp":1760242973666,"version":"build-2065373602"},"reference-count":25,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2015,3,17]],"date-time":"2015-03-17T00:00:00Z","timestamp":1426550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"This study was funded by Genomic Health, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>To assess clinical utility of the 21-gene assay (Oncotype DX\u00ae Recurrence Score\u00ae), we determined whether women with HER2(\u2212)\/ER+ pN1mi breast cancer with low (&lt;18) Recurrence Scores results are given adjuvant chemotherapy in a lower proportion than those with high scores (\u226531). This was a multicenter chart review of \u226518 year old women with pN1mi breast cancer, HER2(\u2212)\/ER+ tumors, ductal\/lobular\/mixed histology, with the assay ordered on or after 1 January 2007. One hundred and eighty one patients had a mean age of 60.7 years; 82.9% had ECOG performance status 0; 33.7% had hypertension, 22.7% had osteoporosis, 18.8% had osteoarthritis, and 8.8% had type-2 diabetes. Mean Recurrence Score was 17.8 (range: 0\u201350). 48.6% had a mastectomy; 55.8% had a lumpectomy. 19.8% of low-risk group patients were recommended chemotherapy vs. 57.9% in the intermediate-risk group and 100% in the high-risk group (p &lt; 0.001). A total of 80.2% of the low-risk group were recommended endocrine therapy alone, while 77.8% of the high-risk group were recommended both endocrine and chemotherapy (p &lt; 0.001). The Oncotype DX Recurrence Score result provides actionable information that can be incorporated into treatment planning for women with HER2(\u2212)\/ER+ pN1mi breast cancer. The Recurrence Score result has clinical utility in treatment planning for HER2(\u2212)\/ER+ pN1mi breast cancer patients.<\/jats:p>","DOI":"10.3390\/ph8010107","type":"journal-article","created":{"date-parts":[[2015,3,17]],"date-time":"2015-03-17T11:04:24Z","timestamp":1426590264000},"page":"107-122","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Retrospective Study of the Impact of 21-Gene Recurrence Score Assay on Treatment Choice in Node Positive Micrometastatic Breast Cancer"],"prefix":"10.3390","volume":"8","author":[{"given":"Thomas","family":"Frazier","sequence":"first","affiliation":[{"name":"Main Line HealthCare Breast Surgical Specialists, Susquehanna Bank Building,  101 South Bryn Mawr Ave, Suite 201, Bryn Mawr, PA 19010, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Fox","sequence":"additional","affiliation":[{"name":"Rena Rowan Breast Center at the Abramson Cancer Center of the University of Pennsylvania,  3400 Civic Center Boulevard, 3 West Pavilion, Philadelphia, PA 19104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Smith","sequence":"additional","affiliation":[{"name":"Penn State Hershey Breast Center, Penn State College of Medicine, 30 Hope Drive, MC EC008, P.O. Box 859, Hershey, Pennsylvania 17033, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Laronga","sequence":"additional","affiliation":[{"name":"Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"McSwain","sequence":"additional","affiliation":[{"name":"The George Washington University, GW Medical Faculty Associates, 2300 M Street,  NW 8th floor, DC Level, Washington, DC 20037, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devchand","family":"Paul","sequence":"additional","affiliation":[{"name":"Rocky Mountain Cancer Centers, 4700 East Hale Parkway, Suite 400, Denver, CO 80220, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Schultz","sequence":"additional","affiliation":[{"name":"University of Maryland St. Joseph Medical Center, 7601 Osler Drive, Towson, MD 21204, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Stilwill","sequence":"additional","affiliation":[{"name":"Midwest Cancer Care Physicians at the Menorah Medical Center, 2316 East Meyer Boulevard,  1 West, Kansas City, MO 64132, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Teal","sequence":"additional","affiliation":[{"name":"The George Washington University, GW Medical Faculty Associates, 2300 M Street,  NW 8th floor, DC Level, Washington, DC 20037, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracey","family":"Weisberg","sequence":"additional","affiliation":[{"name":"The Maine Center for Cancer Medicine, 100 Campus Drive, unit 108, Scarborough, Maine 04074, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Vacchino","sequence":"additional","affiliation":[{"name":"Genomic Health, Inc., 301 Penobscot Drive, Redwood City, CA 94063, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Sing","sequence":"additional","affiliation":[{"name":"Genomic Health, Inc., 301 Penobscot Drive, Redwood City, CA 94063, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dasha","family":"Cherepanov","sequence":"additional","affiliation":[{"name":"Partnership for Health Analytic Research, LLC, 280 S. Beverly Drive, Suite 404, Beverly Hills,  CA 90212, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunice","family":"Chang","sequence":"additional","affiliation":[{"name":"Partnership for Health Analytic Research, LLC, 280 S. Beverly Drive, Suite 404, Beverly Hills,  CA 90212, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Broder","sequence":"additional","affiliation":[{"name":"Partnership for Health Analytic Research, LLC, 280 S. Beverly Drive, Suite 404, Beverly Hills,  CA 90212, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2015,3,17]]},"reference":[{"key":"ref_1","unstructured":"American Cancer Society Cancer Facts & Figures 2015. Atlanta: American Cancer Society. Available online: http:\/\/www.cancer.org\/acs\/groups\/content\/@editorial\/documents\/document\/acspc-044552.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10549-008-9913-8","article-title":"Stage migration due to introduction of the sentinel node procedure: A population-based study","volume":"113","author":"Maaskant","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ejso.2006.04.001","article-title":"Introduction of sentinel node biopsy and stage migration of breast cancer","volume":"32","author":"Bezemer","year":"2006","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1016\/j.suronc.2011.06.006","article-title":"Sentinel lymph node micrometastasis in human breast cancer: An update","volume":"20","author":"Salhab","year":"2011","journal-title":"Surg. Oncol."},{"key":"ref_5","unstructured":"National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Breast Cancer. Version 3. Available online: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0140-6736(04)16981-X","article-title":"National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials","volume":"364","author":"Fisher","year":"2004","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node negative, estrogen receptor-positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","article-title":"Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial","volume":"11","author":"Albain","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2011.0137","article-title":"NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology","volume":"9","author":"Febbo","year":"2011","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/jama.295.14.1658","article-title":"Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer","volume":"295","author":"Berry","year":"2006","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"v277","DOI":"10.1093\/annonc\/mdq200","article-title":"Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines","volume":"21","author":"Bovelli","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/CAD.0b013e3283394624","article-title":"Anticancer therapy induced cardiotoxicity: Review of the literature","volume":"21","author":"Geiger","year":"2010","journal-title":"Anticancer Drugs"},{"key":"ref_14","first-page":"455","article-title":"Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer","volume":"17","author":"Vanderlaan","year":"2011","journal-title":"Am. J. Manag. Care"},{"key":"ref_15","first-page":"e194","article-title":"US insurance program\u2019s experience with a multigene assay for early-stage breast cancer","volume":"17","author":"Hornberger","year":"2011","journal-title":"Am. J. Manag. Care"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1002\/cncr.27443","article-title":"Cost effectiveness of gene expression profiling for early stage breast cancer: A decision-analytic model","volume":"118","author":"Yang","year":"2012","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/jnci\/djr484","article-title":"Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer","volume":"104","author":"Hall","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10549-009-0446-6","article-title":"Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure","volume":"118","author":"Montagna","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1200\/JCO.2008.19.0686","article-title":"Impact of micrometastases in the sentinel node of patients with invasive breast cancer","volume":"27","author":"Hansen","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/01.sla.0000149305.23322.3c","article-title":"Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy","volume":"241","author":"Langer","year":"2005","journal-title":"Ann. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jamcollsurg.2008.10.036","article-title":"Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University\/Anne Arundel Medical Center Sentinel Node Multicenter Study","volume":"208","author":"Reed","year":"2009","journal-title":"J. Am. Coll. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1245\/s10434-009-0804-y","article-title":"Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: A prospective analysis of axillary or distant recurrence","volume":"17","author":"Pernas","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa0904832","article-title":"Micrometastases or isolated tumor cells and the outcome of breast cancer","volume":"361","author":"Borm","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.2009.24.4798","article-title":"Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study","volume":"28","author":"Dowsett","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_25","unstructured":"National Cancer Institute Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients with Invasive RxPONDER Breast Cancer. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 Dec 24]. Available online: http:\/\/clinicaltrials.gov\/show\/NCT01272037."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/8\/1\/107\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:43:37Z","timestamp":1760215417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/8\/1\/107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,17]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,3]]}},"alternative-id":["ph8010107"],"URL":"https:\/\/doi.org\/10.3390\/ph8010107","relation":{},"ISSN":["1424-8247"],"issn-type":[{"type":"electronic","value":"1424-8247"}],"subject":[],"published":{"date-parts":[[2015,3,17]]}}}